These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26304825)

  • 41. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
    Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales.
    Ladhani SN; Andrews NJ; Waight P; Borrow R; Slack MP; Miller E
    Clin Infect Dis; 2014 Feb; 58(4):517-25. PubMed ID: 24300040
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(43):1477-81. PubMed ID: 22048728
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany.
    Rückinger S; van der Linden M; Reinert RR; von Kries R; Burckhardt F; Siedler A
    Vaccine; 2009 Jun; 27(31):4136-41. PubMed ID: 19406190
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):258-61. PubMed ID: 20224542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent advances in pneumococcal vaccination of children.
    Russell FM; Mulholland EK
    Ann Trop Paediatr; 2004 Dec; 24(4):283-94. PubMed ID: 15720885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
    Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
    Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pneumococcal invasive disease in newborns before and after 7-valent and 13-valent universal pneumococcal vaccination in Uruguay].
    Assandri E; Amorín B; Gesuele JP; Algorta G; Pírez MC
    Rev Chilena Infectol; 2015 Apr; 32(2):167-74. PubMed ID: 26065449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factors predictive of increased influenza and pneumococcal vaccination coverage in long-term care facilities: the CMS-CDC standing orders program Project.
    Bardenheier BH; Shefer A; McKibben L; Roberts H; Rhew D; Bratzler D
    J Am Med Dir Assoc; 2005; 6(5):291-9. PubMed ID: 16165069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients.
    Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Hsiao CF; Tseng YT; Su YC; Chang SF; Chang SY; Chang SC
    Vaccine; 2012 May; 30(24):3526-33. PubMed ID: 22484349
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states.
    Imöhl M; Reinert RR; van der Linden M
    Int J Med Microbiol; 2010 Apr; 300(4):237-47. PubMed ID: 19604721
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adults with invasive pneumococcal disease: missed opportunities for vaccination.
    Kyaw MH; Greene CM; Schaffner W; Ray SM; Shapiro M; Barrett NL; Gershman K; Craig AS; Roberson A; Zell ER; Schuchat A; Bennett NM; Whitney CG;
    Am J Prev Med; 2006 Oct; 31(4):286-92. PubMed ID: 16979452
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increasing pneumococcal vaccination rates among hospitalized patients.
    Nowalk MP; Middleton DB; Zimmerman RK; Hess MM; Skledar SJ; Jacobs MA
    Infect Control Hosp Epidemiol; 2003 Jul; 24(7):526-31. PubMed ID: 12887242
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.
    Mitchell R; Trück J; Pollard AJ
    Expert Opin Biol Ther; 2013 Oct; 13(10):1451-65. PubMed ID: 23889554
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
    Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
    Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta.
    Leal J; Vanderkooi OG; Church DL; Macdonald J; Tyrrell GJ; Kellner JD
    Pediatr Infect Dis J; 2012 Sep; 31(9):e169-75. PubMed ID: 22673137
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.
    Ingels H; Rasmussen J; Andersen PH; Harboe ZB; Glismann S; Konradsen H; Hoffmann S; Valentiner-Branth P; Lambertsen L;
    Vaccine; 2012 Jun; 30(26):3944-50. PubMed ID: 22504662
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and haemophilus influenzae type b conjugate vaccine in a Pediatric Referral Hospital in Uruguay.
    Pírez MC; Algorta G; Chamorro F; Romero C; Varela A; Cedres A; Giachetto G; Montano A
    Pediatr Infect Dis J; 2014 Jul; 33(7):753-9. PubMed ID: 24492286
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pneumococcal vaccination in the emergency department: an assessment of need.
    Rudis MI; Stone SC; Goad JA; Lee VW; Chitchyan A; Newton KI
    Ann Emerg Med; 2004 Oct; 44(4):386-92. PubMed ID: 15459621
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation.
    Cordonnier C; Labopin M; Chesnel V; Ribaud P; De La Camara R; Martino R; Ullmann AJ; Parkkali T; Locasciulli A; Yakouben K; Pauksens K; Einsele H; Niederwieser D; Apperley J; Ljungman P;
    Clin Infect Dis; 2009 May; 48(10):1392-401. PubMed ID: 19368505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.